Pathologic and biological prognostic factors of breast cancers in short- and long-term hormone replacement therapy users

Annals of Surgical Oncology

Volumn 9, Issue 3, 2002, Pages 266-271

  Sacchini, Virgilio ^a   Zurrida, Stefano ^b   Andreoni, Gisella ^b   Luini, Alberto ^b   Galimberti, Viviana ^b   Veronesi, Paolo ^b   Intra, Mattia ^b   Viale, Giuseppe ^b   Veronesi, Umberto ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

Breast cancer; Hormone replacement therapy; Prognostic factors; Tumor aggressiveness

Indexed keywords

ESTROGEN; ESTROGEN RECEPTOR; PROGESTERONE;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER INVASION; CANCER STAGING; FEMALE; HUMAN; HUMAN TISSUE; LONG TERM CARE; MAJOR CLINICAL STUDY; PROGNOSIS; SHORT COURSE THERAPY; TUMOR VOLUME;

EID: 0036219284     PISSN: 10689265     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02573064     Document Type: Article

References (42)

1. Postmenopausal hormone therapy and mortality
2. Breast cancer and hormone replacement therapy: Collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer
3. Pathological prognostic factors in breast cancer: The value of histological grade in breast cancer
4. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: A comparison between ABC and unlabeled antibody (PAP) procedures
5. Calretinin: A novel immunocytochemical marker for mesothelioma
6. Ki-67 immunostaining in 322 primary breast cancers: Associations with clinical and pathological variables and prognosis
7. Hormone replacement treatment and breast cancer risk: A cooperative Italian study
8. Prognostic characteristics in breast cancers after hormone replacement therapy
9. Low biologic aggressiveness in breast cancer in women using hormone replacement therapy
10. Estrogen replacement therapy and risk of fatal breast cancer in a prospective cohort of postmenopausal women in the United States
11. Hormone replacement therapy and risk of breast cancer with favorable histology
12. Tumor growth of FGF or VEGF transfected MCF-7 breast carcinoma cells correlates with density of specific microvessels independent of the transfected angiogenic factor
13. Estrogen regulation of cell cycle progression in breast cancer cells
14. Impact of menopausal hormone replacement therapy on clinical and laboratory characteristics of breast cancer
15. Estrogen receptor status (ER) determined by immunohistochemistry (IHC) is superior to biochemical ligand-binding (LB) assay for evaluating breast cancer patients
16. Cytosol estradiol receptor in human mammary carcinoma: An assay based on isoelectric focusing in polyacrylamide gel
17. Steroid receptor measurement in breast cancers: Comparison between ligand binding and enzyme-immunoassay in cytosolic and nuclear extracts
18. Invasive node-negative breast cancer: Multivariate analysis of the prognostic value of peritumoral vessel invasion compared with that of conventional clinico-pathologic features
19. The prognostic value of lymphatic and blood vessel invasion in operable breast cancer
20. Peritumoral vascular invasion in women with node-negative breast cancer, receiving no adjuvant therapy
21. Transdermal oestradiol gel in the treatment of the climacterium: A comparison with oral therapy
22. First European Consensus Conference on the Menopause: Consensus propositions
23. Transdermal oestradiol and cardiovascular risk factors
24. Treatment of postmenopausal osteoporosis with transdermal estrogen
25. Growth hormone treatment induces mammary gland hyperplasia in ageing primates
26. Effect of tamoxifen on serum insulin-like growth factor I levels in stage I breast cancer patients
27. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer
28. Role of insulin-like growth factors in steroid modulated proliferation
29. Effect of estrogen replacement on insulin-like growth factor-I in postmenopausal women: The Rancho Bernardo Study
30. Serum IGF-I and binding proteins 1 and 3 in postmenopausal women and the effects of estrogen
31. Effects of oral and transdermal oestrogen replacement therapy on plasma levels of insulin-like growth factors and IGF binding proteins 1 and 3: A cross-over study
32. Potential impact on breast cancer risk of circulating insulin-like growth factor I modifications induced by oral HRT in menopause
33. Differential effects of oral conjugated estrogens and transdermal estradiol on insulin-like growth factor I, growth hormone and sex hormone binding globulin serum levels
34. Insulin-like growth factor I (IGF-I) serum level modification during transdermal oestradiol treatment in postmenopausal women: A possible bimodal effect depending on basal IGF-I values
35. Comparison of transdermal to oral estradiol administration on hormonal and hepatic parameters in women with premature ovarian failure
36. Pharmacokinetics of estradiol and of estrone during repeated transdermal or oral administration of estradiol
37. Estradiol metabolism during oral and transdermal estradiol replacement therapy in postmenopausal women
38. Update on hormone-replacement therapy
39. Hormone-replacement therapy and tumor grade in breast cancer: Prospective study in screening unit
40. The relationship between breast cancer survival and prior post-menopausal estrogen use